Details

Autor(en) / Beteiligte

• Yang, Yan-Wu
• Ming Yang
• Zhou, Yi-Wu
• Xia, Xin
• Jia, Shu-Li
• Zhao, Yun-Li
• Zhou, Li-Xing
• Cao, Yu
• Ge, Mei-Ling

Titel

Prognostic value of temporal muscle thickness, a novel radiographic marker of sarcopenia, in patients with brain tumor: A systematic review and meta-analysis

Ist Teil von

• Nutrition (Burbank, Los Angeles County, Calif.), 2023-08, Vol.112, p.112077-112077, Article 112077

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• •Thinner temporalis muscle thickness is a novel radiographic biomarker of sarcopenia in patients with brain tumors.•Temporalis muscle thickness was an independent prognostic factor for overall survival in both primary and secondary brain tumors.•The association between thinner temporalis muscle thickness and progression-free survival was significant in patients with primary brain tumors. Sarcopenia has been identified as a prognostic factor among certain types of cancer. However, it is unclear whether there is prognostic value of temporalis muscle thickness (TMT), a potential surrogate for sarcopenia, in adults patients with brain tumors. Therefore, we searched the Medline, Embase, and PubMed to systematically review and meta-analyze the relationship between TMT and overall survival, progression-free survival, and complications in patients with brain tumors and the hazard ratio (HR) or odds ratios (OR), and 95% confidence interval (CI) were evaluated. The quality in prognostic studies (QUIPS) instrument was employed to evaluate study quality. Nineteen studies involving 4570 patients with brain tumors were included for qualitative and quantitative analysis. Meta-analysis revealed thinner TMT was associated with poor overall survival (HR, 1.72; 95% CI, 1.45–2.04; P < 0.01) in patients with brain tumors. Sub-analyses showed that the association existed for both primary brain tumors (HR, 2.02; 95% CI, 1.55-2.63) and brain metastases (HR, 1.39; 95% CI, 1.30-1.49). Moreover, thinner TMT also was the independent predictor of progression-free survival in patients with primary brain tumors (HR, 2.88; 95% CI, 1.85–4.46; P < 0.01). Therefore, to improve clinical decision making it is important to integrate TMT assessment into routine clinical settings in patients with brain tumors.